|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
EP2368578A1
(en)
*
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US7960512B2
(en)
*
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
SV2006002143A
(es)
*
|
2004-06-16 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del cancer resistente al platino
|
|
KR20150043558A
(ko)
*
|
2004-07-22 |
2015-04-22 |
제넨테크, 인크. |
Ｈｅｒ２ 항체 조성물
|
|
JO3000B1
(ar)
*
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
WO2006063042A2
(en)
*
|
2004-12-07 |
2006-06-15 |
Genentech, Inc. |
Selecting patients for therapy with a her inhibitor
|
|
ATE548386T1
(de)
|
2005-01-05 |
2012-03-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
|
|
RU2438705C2
(ru)
|
2005-01-21 |
2012-01-10 |
Дженентек, Инк. |
Введение фиксированных доз her-антител
|
|
CA2596133C
(en)
*
|
2005-02-23 |
2016-11-15 |
Genentech, Inc. |
Extending time to disease progression or survival in cancer patients
|
|
BRPI0607235A2
(pt)
|
2005-02-24 |
2009-08-25 |
Amgen Inc |
mutações do receptor do fator de crescimento epidérmico
|
|
PE20070207A1
(es)
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
|
CA2618681C
(en)
*
|
2005-08-10 |
2015-10-27 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
WO2007090794A1
(en)
*
|
2006-02-10 |
2007-08-16 |
Nerviano Medical Sciences S.R.L. |
Combinations comprising a cdk inhibitor and a growth factor antibody or anti-mitotic
|
|
JP2009529331A
(ja)
*
|
2006-03-10 |
2009-08-20 |
マクロジェニクス，インコーポレーテッド |
変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
|
|
ES2489646T3
(es)
*
|
2006-05-26 |
2014-09-02 |
Macrogenics, Inc. |
Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
|
|
CA2656224C
(en)
*
|
2006-06-26 |
2018-01-09 |
Macrogenics, Inc. |
Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
|
|
PT2029173T
(pt)
|
2006-06-26 |
2016-11-02 |
Macrogenics Inc |
Anticorpos específicos fc rib e seus métodos de uso
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
EP1878747A1
(en)
|
2006-07-11 |
2008-01-16 |
greenovation Biotech GmbH |
Glyco-engineered antibodies
|
|
WO2008073160A2
(en)
*
|
2006-08-17 |
2008-06-19 |
The Trustees Of Columbia University In The City Of New York |
Methods for converting or inducing protective immunity
|
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
|
AU2008223069B2
(en)
|
2007-03-02 |
2012-12-13 |
F. Hoffmann-La Roche Ag |
Predicting response to a HER dimerisation inhibitor based on low HER3 expression
|
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
|
ES2975748T3
(es)
|
2007-06-26 |
2024-07-12 |
F Star Therapeutics Ltd |
Presentación de agentes de unión
|
|
AU2008280105B2
(en)
*
|
2007-07-24 |
2011-10-20 |
Novartis Ag |
Use of imidazoquinolines for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
|
|
RU2370280C2
(ru)
*
|
2007-10-08 |
2009-10-20 |
Институт физико-химической биологии им. А.Н.Белозерского |
СПОСОБ СУПЕРПРОДУКЦИИ В РАСТЕНИИ АНТИТЕЛ ПРОТИВ ОНКОГЕНА HER2/neu
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
US8669349B2
(en)
|
2008-04-02 |
2014-03-11 |
Macrogenics, Inc. |
BCR-complex-specific antibodies and methods of using same
|
|
US8802093B2
(en)
|
2008-04-02 |
2014-08-12 |
Macrogenics, Inc. |
HER2/neu-specific antibodies and methods of using same
|
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
|
JP2010006705A
(ja)
*
|
2008-06-13 |
2010-01-14 |
Atlas Antibodies Ab |
Ｈｅｒ２サブセット
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
|
CN102753193A
(zh)
|
2008-10-31 |
2012-10-24 |
比奥根艾迪克Ma公司 |
Light靶向分子及其用途
|
|
WO2010099153A2
(en)
*
|
2009-02-25 |
2010-09-02 |
Merck Sharp & Dohme Corp. |
Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris
|
|
US20110313137A1
(en)
*
|
2009-02-25 |
2011-12-22 |
Dongxing Zha |
Her2 antibody compositions
|
|
US8064431B2
(en)
*
|
2009-07-14 |
2011-11-22 |
Level 3 Communications, Llc |
One way information transmission method
|
|
US8401035B2
(en)
*
|
2009-07-14 |
2013-03-19 |
Level 3 Communications, Llc |
One way SRS information transmission method
|
|
US9345661B2
(en)
*
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
JP6184695B2
(ja)
|
2009-12-04 |
2017-08-23 |
ジェネンテック， インコーポレイテッド |
多重特異性抗体、抗体アナログ、組成物、及び方法
|
|
EP2513148B1
(en)
*
|
2009-12-16 |
2016-08-31 |
AbbVie Biotherapeutics Inc. |
Anti-her2 antibodies and their uses
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
LT2542256T
(lt)
|
2010-03-04 |
2019-10-25 |
Macrogenics Inc |
Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
|
|
RU2425840C1
(ru)
*
|
2010-04-09 |
2011-08-10 |
Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") |
АНТИТЕЛО, СПЕЦИФИЧЕСКИ ВЗАИМОДЕЙСТВУЮЩЕЕ С ОНКОБЕЛКОМ HER2/neu
|
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
|
WO2011130580A1
(en)
|
2010-04-15 |
2011-10-20 |
Alper Biotech, Llc |
Monoclonal antibodies against her2 antigens, and uses therefor
|
|
AU2011250970B2
(en)
|
2010-05-10 |
2016-12-15 |
Sinica, Academia |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
|
WO2011147982A2
(en)
|
2010-05-27 |
2011-12-01 |
Genmab A/S |
Monoclonal antibodies against her2 epitope
|
|
JP6320753B2
(ja)
|
2010-05-27 |
2018-05-09 |
ゲンマブ エー／エス |
Ｈｅｒ２に対するモノクローナル抗体
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
MX348637B
(es)
|
2010-11-01 |
2017-06-22 |
Symphogen As |
Anticuerpos y composiciones anti-her3.
|
|
CN103702967A
(zh)
|
2011-03-14 |
2014-04-02 |
貝丝以色列女执事医疗中心 |
用于治疗增殖性病症的方法和组合物
|
|
AU2012245116A1
(en)
|
2011-04-20 |
2013-11-07 |
Genmab A/S |
Bispecific antibodies against HER2 and CD3
|
|
CA2843158A1
(en)
|
2011-08-26 |
2013-03-07 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
CN104334189A
(zh)
|
2011-10-14 |
2015-02-04 |
霍夫曼-拉罗奇有限公司 |
Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
|
|
WO2013083810A1
(en)
|
2011-12-09 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
|
RU2627185C1
(ru)
*
|
2012-03-16 |
2017-08-03 |
Коваген Аг |
Новые связывающие молекулы с противоопухолевой активностью
|
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
|
AU2013251165B2
(en)
|
2012-04-17 |
2017-08-24 |
Arsanis Biosciences Gmbh |
Cross-reactive Staphylococcus aureus antibody
|
|
ES2431914B2
(es)
*
|
2012-04-27 |
2014-07-24 |
Universidad De Cádiz |
Anticuerpo monoclonal humano ANTI-HER2
|
|
CN104379604A
(zh)
*
|
2012-05-24 |
2015-02-25 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体
|
|
EP2858648B1
(en)
|
2012-06-07 |
2018-08-22 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for the inhibition of pin1
|
|
US9738724B2
(en)
|
2012-06-08 |
2017-08-22 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
WO2014004639A1
(en)
|
2012-06-26 |
2014-01-03 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
|
US20160038490A1
(en)
*
|
2012-07-18 |
2016-02-11 |
Angion Biomedica Corp. |
Compositions and methods for treating dysproliferative diseases
|
|
KR102193080B1
(ko)
|
2012-08-13 |
2020-12-18 |
제넨테크, 인크. |
항-jagged 항체 및 사용 방법
|
|
US9914956B2
(en)
|
2012-08-18 |
2018-03-13 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
|
AU2013305827A1
(en)
|
2012-08-21 |
2015-03-05 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
|
CA2941485C
(en)
|
2012-10-12 |
2018-06-12 |
Philip Wilson Howard |
Pyrrolobenzodiazepines and conjugates thereof
|
|
AU2013337926B2
(en)
|
2012-10-30 |
2017-12-21 |
Esperance Pharmaceuticals, Inc. |
Antibody/drug conjugates and methods of use
|
|
EP2738180A1
(en)
*
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
MX363188B
(es)
|
2012-11-30 |
2019-03-13 |
Hoffmann La Roche |
Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
|
|
HK1213481A1
(zh)
*
|
2012-12-13 |
2016-07-08 |
The Trustees Of The University Of Pennsylvania |
Dna抗体构建体及其使用方法
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
TW201444872A
(zh)
|
2013-03-06 |
2014-12-01 |
Merrimack Pharmaceuticals Inc |
抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
|
|
US20160031887A1
(en)
|
2013-03-13 |
2016-02-04 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CN106211758B
(zh)
|
2013-04-09 |
2021-03-23 |
北京强新生物科技有限公司 |
2-乙酰基萘并[2,3-b]呋喃-4,9-二酮用于治疗癌症的用途
|
|
CA2907776C
(en)
*
|
2013-04-16 |
2020-04-14 |
Genentech, Inc. |
Pertuzumab variants and evaluation thereof
|
|
WO2014182970A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
KR101453462B1
(ko)
|
2013-05-16 |
2014-10-23 |
앱클론(주) |
Her2에 특이적으로 결합하는 항체
|
|
EP3013365B1
(en)
|
2013-06-26 |
2019-06-05 |
Academia Sinica |
Rm2 antigens and use thereof
|
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
|
CN105682666B
(zh)
|
2013-09-06 |
2021-06-01 |
中央研究院 |
使用醣脂激活人类iNKT细胞
|
|
KR20160083949A
(ko)
|
2013-11-13 |
2016-07-12 |
자임워크스 인코포레이티드 |
Egfr 및/또는 her2를 표적화하는 1가 항원 결합 작제물 및 이의 용도
|
|
RS62157B1
(sr)
|
2013-11-19 |
2021-08-31 |
Remegen Co Ltd |
Anti-her2 antitelo i njegov konjugat
|
|
PT3074424T
(pt)
|
2013-11-27 |
2025-05-29 |
Zymeworks Bc Inc |
Construções de ligação a antigénio biespecíficas direcionadas a her2
|
|
KR20160099087A
(ko)
|
2013-12-20 |
2016-08-19 |
에프. 호프만-라 로슈 아게 |
이중특이성 her2 항체 및 사용 방법
|
|
JP6130517B2
(ja)
|
2013-12-25 |
2017-05-17 |
第一三共株式会社 |
抗ｔｒｏｐ２抗体−薬物コンジュゲート
|
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
AU2015206370A1
(en)
|
2014-01-16 |
2016-07-07 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
PL4212552T3
(pl)
|
2014-01-31 |
2025-03-17 |
Daiichi Sankyo Company, Limited |
Koniugat przeciwciało anty-her2-lek
|
|
JP6935195B2
(ja)
|
2014-03-11 |
2021-09-15 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
|
|
MX2016011821A
(es)
|
2014-03-11 |
2017-04-27 |
Molecular Templates Inc |
Proteinas que comprenden regiones efectoras de subunidad a de toxina shiga proximas a amino terminal y regiones de union de tipo inmunoglobulina de direccionamiento selectivo celular.
|
|
CN106164094B
(zh)
*
|
2014-03-21 |
2021-05-14 |
X博迪公司 |
双特异性抗原结合多肽
|
|
EP3129767B1
(en)
|
2014-03-27 |
2021-09-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
|
ES2754348T3
(es)
|
2014-04-10 |
2020-04-17 |
Daiichi Sankyo Co Ltd |
Conjugado de (anticuerpo anti-HER2)-fármaco
|
|
US10780182B2
(en)
|
2014-04-25 |
2020-09-22 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
|
AU2015249633B2
(en)
|
2014-04-25 |
2020-10-15 |
Genentech, Inc. |
Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
|
|
CA2950415A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
|
EP4116329A1
(en)
|
2014-05-27 |
2023-01-11 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
CA2950577A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Fucosidase from bacteroides and methods using the same
|
|
WO2015184001A1
(en)
|
2014-05-28 |
2015-12-03 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
|
US10351914B2
(en)
|
2014-07-17 |
2019-07-16 |
Beth Israel Deaconess Medical Center, Inc. |
Biomarkers for Pin1-associated disorders
|
|
US9968579B2
(en)
|
2014-07-17 |
2018-05-15 |
Beth Isreal Deaconess Medical Center, Inc. |
ATRA for modulating Pin1 activity and stability
|
|
KR101608301B1
(ko)
|
2014-08-22 |
2016-04-12 |
앱클론(주) |
Her2에 특이적으로 결합하는 항체
|
|
EP3191500A4
(en)
|
2014-09-08 |
2018-04-11 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
|
|
JP6531166B2
(ja)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
|
HUE052460T2
(hu)
|
2014-09-12 |
2021-04-28 |
Genentech Inc |
Anti-HER2 antitestek és immunkonjugátumok
|
|
WO2016044396A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
|
CN104225594B
(zh)
*
|
2014-09-23 |
2016-03-23 |
合肥瀚科迈博生物技术有限公司 |
抗her2人源化抗体及其相关的抗肿瘤组合物
|
|
ES3014819T3
(en)
|
2014-11-27 |
2025-04-25 |
Zymeworks Bc Inc |
Methods of using bispecific antigen-binding constructs targeting her2
|
|
CA2969214A1
(en)
|
2014-12-01 |
2016-06-09 |
The Trustees Of The University Of Pennsylvania |
Dna antibody constructs and method of using same
|
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
KR102691114B1
(ko)
|
2015-01-24 |
2024-08-01 |
아카데미아 시니카 |
신규한 글리칸 콘주게이트 및 이를 사용하는 방법
|
|
CN105985435B
(zh)
*
|
2015-01-30 |
2019-10-15 |
嘉和生物药业有限公司 |
全人源her2抗体的突变抗体及其编码基因和应用
|
|
WO2016145186A1
(en)
|
2015-03-12 |
2016-09-15 |
Beth Israel Deaconess Medical Center, Inc. |
Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
|
|
WO2016168766A1
(en)
*
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Optimized chimeric receptor t cell switches and uses thereof
|
|
WO2016179707A1
(en)
|
2015-05-13 |
2016-11-17 |
Zymeworks Inc. |
Antigen-binding constructs targeting her2
|
|
DK3302551T3
(da)
|
2015-05-30 |
2024-08-26 |
Hoffmann La Roche |
Fremgangsmåder til behandling af HER2-positiv tidligere ubehandlet metastatisk brystkræft
|
|
CA2984635A1
(en)
|
2015-05-30 |
2016-12-08 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
|
TW201717935A
(zh)
|
2015-06-03 |
2017-06-01 |
波士頓生醫公司 |
用於治療癌症的組成物和方法
|
|
IL290959B2
(en)
|
2015-06-29 |
2023-04-01 |
Daiichi Sankyo Co Ltd |
Preparations containing antibody-drug conjugates and methods for their production
|
|
EP3325510A2
(en)
|
2015-07-26 |
2018-05-30 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
|
CN105132357B
(zh)
*
|
2015-07-29 |
2019-12-06 |
苏州诺普再生医学有限公司 |
一种用于表皮细胞培养的无血清培养体系
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
US11591382B2
(en)
|
2015-09-22 |
2023-02-28 |
Genentech, Inc. |
Expression of Fc-containing proteins
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
CN108779174B
(zh)
*
|
2015-11-04 |
2022-11-29 |
希望之城公司 |
靶向her2的嵌合抗原受体
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
TWI727380B
(zh)
|
2015-11-30 |
2021-05-11 |
美商輝瑞股份有限公司 |
位點專一性ｈｅｒ２抗體藥物共軛體
|
|
CN109195996A
(zh)
|
2016-03-08 |
2019-01-11 |
中央研究院 |
N-聚醣及其阵列的模组化合成方法
|
|
RU2648161C2
(ru)
*
|
2016-04-01 |
2018-03-22 |
Юрий Леонидович Дорохов |
Способ получения антитела, специфически связывающего домен димеризации экзоклеточной части онкобелка HER2/neu, в растении, антитело, полученное этим способом, и его применение
|
|
GEAP202214922A
(en)
|
2016-04-15 |
2022-02-10 |
Macrogenics Inc |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
|
|
KR101923624B1
(ko)
|
2016-07-28 |
2018-11-30 |
고려대학교 산학협력단 |
암세포 화학요법을 위한 agtr1 압타머-항암약물 복합체
|
|
EP3500594A4
(en)
|
2016-08-22 |
2020-03-11 |
Cho Pharma Inc. |
ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
|
|
WO2018069289A1
(en)
|
2016-10-11 |
2018-04-19 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
|
TW201818940A
(zh)
|
2016-11-04 |
2018-06-01 |
美商建南德克公司 |
Her2陽性乳癌之治療
|
|
KR101923641B1
(ko)
|
2016-11-25 |
2018-11-29 |
재단법인 목암생명과학연구소 |
항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
|
|
US11299469B2
(en)
|
2016-11-29 |
2022-04-12 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
TW202508642A
(zh)
|
2016-12-12 |
2025-03-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途
|
|
JP6914336B2
(ja)
|
2016-12-28 |
2021-08-04 |
ジェネンテック， インコーポレイテッド |
進行したｈｅｒ２発現がんの治療
|
|
US20190336533A1
(en)
|
2016-12-28 |
2019-11-07 |
Green Cross Lab Cell Corporation |
Chimeric antigen receptor and natural killer cells expressing same
|
|
TWI780104B
(zh)
|
2017-01-17 |
2022-10-11 |
日商第一三共股份有限公司 |
抗ｇｐｒ２０抗體及抗ｇｐｒ２０抗體-藥物結合物、以及其製造方法及用途
|
|
EP3868404A1
(en)
|
2017-01-17 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Subcutaneous her2 antibody formulations
|
|
CN110312736B
(zh)
|
2017-01-23 |
2023-05-09 |
苏州康宁杰瑞生物科技有限公司 |
Pd-l1结合多肽或化合物
|
|
AU2018213194B2
(en)
|
2017-01-25 |
2023-01-12 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes
|
|
US11834506B2
(en)
|
2017-02-08 |
2023-12-05 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
US11884732B2
(en)
*
|
2017-02-20 |
2024-01-30 |
Dragonfly Therapeutics, Inc. |
Proteins binding HER2, NKG2D and CD16
|
|
US11077189B2
(en)
|
2017-03-02 |
2021-08-03 |
Genentech Inc. |
Adjuvant treatment of HER2-positive breast cancer
|
|
US11207420B2
(en)
|
2017-04-19 |
2021-12-28 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Cytotoxin and conjugate, uses of same and preparation method therefor
|
|
CA3059241A1
(en)
|
2017-04-24 |
2018-11-01 |
Genentech, Inc. |
Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
TW202530219A
(zh)
|
2017-05-15 |
2025-08-01 |
日商第一三共股份有限公司 |
抗體－藥物結合物之製造方法
|
|
JP2020520923A
(ja)
|
2017-05-17 |
2020-07-16 |
ボストン バイオメディカル， インコーポレイテッド |
がんを処置するための方法
|
|
EP3677589B1
(en)
|
2017-08-31 |
2025-11-26 |
Daiichi Sankyo Company, Limited |
Improved method for producing antibody-drug conjugate
|
|
CN117838881A
(zh)
|
2017-08-31 |
2024-04-09 |
第一三共株式会社 |
制备抗体-药物缀合物的新方法
|
|
EP3688023B1
(en)
|
2017-09-25 |
2025-08-27 |
Shihuida Pharmaceutical Group (Jilin) Co., Ltd. |
Methods and compositions for cancer treatment
|
|
JP7386796B2
(ja)
*
|
2017-11-14 |
2023-11-27 |
グリーン クロス ラボ セル コーポレーション |
抗－ｈｅｒ２抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体
|
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
KR20200099123A
(ko)
|
2017-12-15 |
2020-08-21 |
쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 |
생체활성 접합체, 이의 제조 방법 및 용도
|
|
US12384847B2
(en)
|
2018-02-08 |
2025-08-12 |
Dragonfly Therapeutics, Inc. |
Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
|
|
DK3749346T3
(da)
|
2018-02-08 |
2024-09-09 |
Dragonfly Therapeutics Inc |
Antistof variable domænekombinationer rettet mod nkg2d-receptoren
|
|
SG11202007945UA
(en)
|
2018-02-20 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
US20210221894A1
(en)
*
|
2018-04-03 |
2021-07-22 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
|
|
EP3774900A1
(en)
|
2018-04-13 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
|
AU2019257343A1
(en)
|
2018-04-17 |
2020-09-10 |
Molecular Templates, Inc. |
HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
|
|
BR112020023373A2
(pt)
|
2018-05-18 |
2021-02-09 |
Daiichi Sankyo Company, Limited |
conjugado, composição, e, uso de um conjugado ou de uma composição
|
|
BR112020023846A2
(pt)
|
2018-05-23 |
2021-04-13 |
Adc Therapeutics Sa |
Adjuvante molecular
|
|
US12168691B2
(en)
|
2018-05-31 |
2024-12-17 |
Board Of Regents, The University Of Texas System |
VHS format bi-specific antibodies specific for HER2 and VEGF and use thereof
|
|
TWI846717B
(zh)
|
2018-07-27 |
2024-07-01 |
日商第一三共股份有限公司 |
辨識抗體-藥物結合物之藥物部位的蛋白質
|
|
SG11202100947SA
(en)
|
2018-07-31 |
2021-03-30 |
Daiichi Sankyo Co Ltd |
Treatment of metastatic brain tumor by administration of antibody-drug conjugate
|
|
SG11202100663VA
(en)
|
2018-08-01 |
2021-02-25 |
Cephalon Inc |
Anti-cxcr2 antibodies and uses thereof
|
|
PE20211860A1
(es)
|
2018-08-08 |
2021-09-21 |
Dragonfly Therapeutics Inc |
Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
BR112021002276A2
(pt)
|
2018-08-08 |
2021-05-04 |
Dragonfly Therapeutics, Inc. |
proteínas de ligação a nkg2d, cd16 e um antígeno associado ao tumor
|
|
SG11202102377YA
(en)
|
2018-09-10 |
2021-04-29 |
Mirati Therapeutics Inc |
Combination therapies
|
|
HUE060916T2
(hu)
|
2018-10-15 |
2023-04-28 |
Hoffmann La Roche |
Eljárások reziduális emlõrák trasztuzumab-emtanzinnal történõ kezelésére
|
|
WO2020084503A1
(en)
|
2018-10-26 |
2020-04-30 |
Cadila Healthcare Limited |
A composition comprising antibody with reduced level of basic variants thereof
|
|
CN113677403B
(zh)
|
2019-04-12 |
2024-12-27 |
豪夫迈·罗氏有限公司 |
包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
|
|
KR20220115566A
(ko)
|
2019-11-15 |
2022-08-17 |
시아겐 인크. |
항-her2 항체-약물 접합체와 조합된 투카티닙으로 her2 양성 유방암을 치료하는 방법
|
|
CA3081503A1
(en)
|
2019-12-06 |
2021-06-06 |
Zymeworks Inc. |
Methods of using a bispecific antigen-binding construct targeting her2 in combination with cdk4/6 inhibitors for the treatment of breast cancer
|
|
TWI874613B
(zh)
*
|
2020-03-17 |
2025-03-01 |
美商西雅圖免疫公司 |
微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
|
|
US12157771B2
(en)
|
2020-05-06 |
2024-12-03 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and CLEC12A
|
|
PH12022553167A1
(en)
|
2020-06-23 |
2024-03-04 |
Hoffmann La Roche |
Agonistic cd28 antigen binding molecules targeting her2
|
|
WO2022005499A1
(en)
|
2020-06-29 |
2022-01-06 |
Genentech, Inc. |
Pertuzumab plus trastuzumab fixed dose combination
|
|
IL299121A
(en)
|
2020-07-14 |
2023-02-01 |
Hoffmann La Roche |
Tests for fixed dose combinations
|
|
WO2022079211A1
(en)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugates
|
|
CN120093941A
(zh)
|
2021-02-09 |
2025-06-06 |
苏州宜联生物医药有限公司 |
生物活性物偶联物及其制备方法和用途
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
AU2022279185A1
(en)
|
2021-05-19 |
2024-01-04 |
Shanghai De Novo Pharmatech Co., Ltd. |
Nitrogen-containing compound, conjugate containing said compound, and application thereof
|
|
EP4386006A1
(en)
|
2021-07-05 |
2024-06-19 |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd. |
Antibody-drug conjugate and application thereof
|
|
CN117460540A
(zh)
|
2021-07-22 |
2024-01-26 |
上海森辉医药有限公司 |
艾日布林衍生物的药物偶联物
|
|
KR20240095442A
(ko)
|
2021-11-03 |
2024-06-25 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
항체의 특이적 접합
|
|
CA3252323A1
(en)
*
|
2022-02-19 |
2023-08-24 |
Salvitus, Inc. |
PROBIOTIC VACCINES AND ASSOCIATED METHODS OF USE
|
|
TW202421207A
(zh)
|
2022-09-30 |
2024-06-01 |
大陸商上海迪諾醫藥科技有限公司 |
苯并氮雜卓衍生物、含其的偶聯物及其應用
|
|
CN118873678A
(zh)
|
2023-01-18 |
2024-11-01 |
泰励生物科技（上海）有限公司 |
抗体偶联药物及其用途
|
|
WO2024173565A2
(en)
*
|
2023-02-14 |
2024-08-22 |
New York University |
Human synthetic antibodies targeting human epidermal growth factor receptor 2 (her2) mutants
|
|
WO2025019254A1
(en)
|
2023-07-14 |
2025-01-23 |
Guardant Health, Inc. |
Classification of breast tumors using dna methylation from liquid biopsy
|
|
CN120058948B
(zh)
*
|
2023-11-30 |
2025-12-30 |
粤港澳大湾区精准医学研究院(广州) |
一种抗人her2的单克隆抗体及其应用
|